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Abstract Mexico, like many other middle-income
countries, is experiencing a demographic and epidemio-
logical transition resulting in an older population suffering
from chronic diseases. At the present time, cancer is the
second cause of death in the country. Until recently, cer-
vical carcinoma was the most frequent type of cancer in the
country, however, the incidence of breast, prostate and
colon cancers is growing. The demand for health care and
health expenditure represented by cancer treatment chal-
lenges the limited resources the country has, particularly as
patients seek treatment in advanced stages of the disease.
Interestingly enough, these types of cancers could be
detected in the early stages with rather simple screening
procedures. The purpose of this paper is to describe the
Mexican health system, and the impact of its fragmentation
on access to medicines. Focusing on colorectal cancer
(CRC), we describe its epidemiology, screening procedures
and the inequities in health care access for these patients.
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Country proﬁle
The Mexican health-care system is, organisationally, dif-
ferent from other OECD countries. The fragmented health
system is characterised by the presence of several public
purchasers that are vertically integrated with providers, and
serve different parts of the population with little inter-
connection. In addition, there is a very large, and mostly
unregulated, private sector [1]. The country’s health
expenditure is one of the lowest among the OECD coun-
tries (6.6% GDP 2006). Mexico does not have a single,
national scheme providing health care coverage as a whole.
Access to health care, insurance coverage and health out-
comes vary across regions, and are characterised by a
relatively low level of public spending with a high burden
of out-of-pocket expenditure [2].
The Mexican health-care system
Approximately half the population enjoys social insurance
coverage for health care, including pharmaceuticals. The
other half of the population relies on federal and state-
funded services, with the exception of a minority which has
private health insurance. Social insurance is compulsory
for all salaried workers in the formal labour market. The
socially insured population receives health care at the In-
stituto Mexicano del Seguro Social (IMSS, Mexican
Institute of Social Services) and at the Instituto de Segur-
idad y Servicios Sociales de los Trabajadores Del Estado
(ISSSTE, Institute of Security and Social Services for
Government Workers). The IMSS and ISSSTE beneﬁcia-
ries and their dependents are covered for most health-care
services, including most prescription pharmaceuticals
included in their respective formularies, and receive health
E. Verastegui (&)
Unidad de Etica Clinica, Instituto Nacional de Cancerologia,
Av. San Fernando 22, 14080 Mexico City, Mexico
e-mail: unidadbioetica@incan.edu.mx
A. Mohar
Instituto Nacional de Cancerologia, Av. San Fernando 22,
14080 Mexico City, Mexico
e-mail: amohar@incan.edu.mx
123
Eur J Health Econ (2010) 10 (Suppl 1):S107–S114
DOI 10.1007/s10198-009-0190-1care at no out-of-pocket cost, as long as using providers
employed by the IMSS or ISSSTE.
The uninsured population obtain health-care services
through the Ministry of Health (MoH) or state health ser-
vices facilities
1, subject to an evaluation of socio-economic
status; however, patients must pay out-of-pocket for any
drugs. Recent reforms have established a public health
insurance scheme, the Seguro Popular de Salud, or Popular
Health Insurance, covering drug costs for patients enrolled
in the programme based on a catalogue of 249 essential
interventions and 17 interventions (mostly high-specialty)
relating to catastrophic expenditures [3]. Private insurance
in Mexico is very limited. At present, only 3% of the
population, mostly high-income individuals, has private
insurance with employer-subsidised group plans account-
ing for half of private health insurance coverage.
The public sector, whether state (MoH) or social secu-
rity (IMSS, ISSSTE), provides health services at all levels
of care in their own facilities (23,269 medical facilities).
The private hospital sector provides around one-third of all
hospital beds in the country (4,103 hospitals with 3,082
private) [4, 5]. Nearly half of the private hospital facilities
are concentrated in Mexico City, while richer states have a
greater availability of private sector facilities than poorer
states [1, 5]. Private sector hospitals in Mexico are quite
diverse: small physician-owned clinics with fewer than ﬁve
beds account for 27% of private hospital beds [6]. Over
half of private hospitals do not have X-ray units; about one-
third do not have a full-time doctor [1]. Only 3% of private
hospital beds are in hospitals with more than 50 beds.
These hospitals provide high-tech and highly specialised
care.
The country is undergoing demographic and epidemio-
logical transition,
2 with mortality and morbidity patterns in
most states having increasing chronic and lifestyle-related
illnesses,
3 ultimately placing greater pressure on health
care systems.
4 Furthermore, the social security sector is
facing pressures from within as a result of increasing
pension payments for its own workers.
Pharmaceutical expenditure
Mexico has witnessed growth rates in health expenditure
surpassing general rates of inﬂation, primarily due to
pharmaceutical costs. Although the country has the lowest
per capita income among most OECD countries, pharma-
ceutical expenditure is much higher than total health
spending, with one of the highest percentages of GDP [5].
However, yearly PPP average expenditure is only $138.00
USD (€ 95) compared to $792.00 USD (€ 535) in the US
[7]. Drug prices in Mexico are about 80% of American
prices; nevertheless, when prices are adjusted for income,
differences in pharmaceutical prices are more than ﬁve
times the income-adjusted level [5]. Furthermore, about
90% of the pharmaceutical expenditure comes from private
agents [8].
A large proportion of individuals without access to
social security (IMSS, ISSSTE) protection belong to the
poorest segments of the population, and a high share of
households in lower-income quintiles face catastrophic and
poverty-creating health-care expenditures.
Expenditure and resource allocation
A consequence of half the population without health
insurance coverage is a large discrepancy in total dispos-
able income devoted to health care [9]. The social security
(IMSS, ISSSTE) agencies, the MoH and the Mexican states
health authorities are obliged to purchase their pharma-
ceuticals from two sets of positive lists: the Cuadro Ba ´sico,
or Basic Formulary, and the Cata ´logo de Insumos, or
Catalogue of Inputs [5].
Approval of a new drug for the formulary is made by the
Inter Institutional Commission. All requests for formulary
inclusion must follow a bylaw stipulating three criteria:
drugs must have marketing authorisation, meet all safety
and clinical tests, and be cost-effective. With regards to the
last criterion, the applicant must submit with the request all
pharmaco-economic tests pertaining to the drug. The bylaw
is currently being revised to make the cost-effectiveness
criterion, which has been in place for only 2 years, more
explicit and to clarify its implementation [5].
Public purchasers procure pharmaceuticals for dispen-
sation in publicly owned and operated pharmacies. Except
for drugs with patents, all medicines purchased by public-
sector institutions must follow a set of regulations (i.e.
public biddings).
The IMSS is the most important pharmaceutical buyer,
purchasing 883 different pharmaceuticals in 2005, of which
99 (11%) were patented. Private hospitals drug purchases
work through negotiations with both distributors and
manufacturers. Typically, hospitals buy the latest drugs
1 Mexico’s health system is decentralised, each state has its own
secretariat of health and provides only for their region. This paper will
use generically the MoH, but this will also cover state services.
2 Mexico’s current population is approximately 109 million people,
and by 2025, almost 10% of the Mexican population is estimated to
be over 65; this percentage is expected to double by 2050.
3 However, in states with lower levels of socio-economic develop-
ment and in rural areas, a considerable epidemiological backlog
remains.
4 The burden of chronic diseases has increased, and cancer is the
second cause of mortality after cardiovascular diseases.
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123directly from producers, and the purchasing institution can
enter into direct negotiations with the producer [5].
Most public pharmaceutical expenditures are made by
the IMSS and ISSSTE. Public pharmaceutical expenditure
as a proportion of total pharma expenditure was 8.2% in
2002, 10.4% in 2003 and 11.6% in 2004 [10].
Budgetary constraints have limited both the quantity and
quality of care to the poor, leading to signiﬁcant implicit
rationing throughout the system; for example, availability
of most drugs in the MoH is extremely poor. There is also
wide variability in quality across and within both the public
and private sectors.
Of all drugs released globally between 1995 and 2001,
most new products had been marketed in Mexico within
4 years of the ﬁrst global launch, and 73% were available
within 5 years [11]. The launching of new drugs is slower
than in most developed countries (where a majority of new
drugs are launched within 3 years), but similar to OECD
countries such as Spain and Austria, while better than
countries such as Portugal. To some extent, manufacturer’s
decisions regarding product launch (and pricing) in Mexico
are likely to be affected by Mexico’s proximity to the US
who provides the largest market for pharmaceuticals
globally and at highest prices. The US is the largest single
exporter of drugs to the Mexican pharmaceutical market,
supplying about one-quarter of total imports [12].
Costly treatments are only available in specialised hos-
pitals, which are mainly located in highly populated urban
areas. For cancer patients, new drugs are sometimes
available at some hospitals of the social security system.
For private patients and patients receiving health care at the
State health system (including the Instituto Nacional de
Cancerologia, INCan), most new drugs are available, but
with out-of-pocket payments.
Physicians have access to new drugs, often through
phase three clinical trials required by the regulatory
authorities before a registration is granted or phase four
trials. Although therapeutic-diagnostic guides are distrib-
uted to physicians, enforcement is neither regulated nor
sanctioned.
Cancer registries and data sources
The fragmentation of the institutional arrangements, com-
bined with provider decentralisation, contributes to poor
quality of statistical data available in Mexico [3]. In the
absence of a National Cancer Registration System, the
Registro Histopatologico de las Neoplasias de Mexico
(RHNM) is the primary information source. The most
recent information available [13] reported 150,000 total
new cancer cases [14]. Most patients were seen at the IMSS
(36.3%), followed by private hospitals (26.7%), Secretariat
of Health hospitals (22.8%), and armed forces and PEMEX
(Mexican oil company)
5 (14.2%). Of these new cases,
cervical and breast cancers were most frequent in women,
and prostate and lung cancers in men. According to De la
Garza [15] during 2008, 28,883 women, 26,846 men and
1,630 children died from malignant diseases.
Screening
In 1994, the MoH established the National Programme for
the Prevention and Control of Cervical Cancer. After
10 years of a massive campaign promoting pap smears for
Mexican women and also an increase in the number of
clinics, reports show more than 6.5 million women have
been screened for cervical cancer [15, 16].
At the beginning of the present Government Adminis-
tration, a National Health Programme 2007–2012 was
developed, in order to achieve its targets by the year 2030
[17]. This Program has ﬁve different goals (improve pop-
ulation health, decrease inequities, provide quality health
care, health promotion), ten approaches that will give
administrative viability and sustainability, through 74 lines
of action [17].
An important line of action is the National Programme
for Cancer Control (PNCC), which includes ﬁve central
themes:
1. Prevention and early detection of cancer
2. Development of oncology diagnosis and treatment
guidelines for the ten most frequent neoplasms in
Mexico
3. Implementation of palliative care
4. Improvement of medical infrastructure and medical
services administration
5. Enforcement of the control of tobacco consumption
Total expenditure for women programs in 2005 was 38
110.80 million Pesos (€ 8.9 millions), representing 8.5% of
total health expenditure and 0.5% of GDP [18]. The pro-
grams were ﬁnanced with public funds (64.5%), and only
35.5% were funded out-of-pocket. In contrast, total health
expenditure has greater private than public funding (56.5
vs. 43.5%). Screening programmes and treatment for cer-
vical cancer represent 4.5% of total health expenditure
[18]. During 2000–2005, a decrease in cancer mortality
was reported (15.7/1,000,000 women), as a result of an
improvement in cervical screening programmes now cov-
ering 70% of women aged 25 years and older [19–21].
5 The type of cancers diagnosed have changed during the last decade,
the incidence of cervical carcinoma has decreased and breast, prostate
and colon cancer incidences have increased.
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free access to cervical cancer treatment, including surgery,
radiation therapy and chemotherapy via the social protec-
tion plan insurance programme [22].
Breast cancer is a serious threat to the health of women
globally, and an unrecognised priority in middle-income
countries. In Mexico, mortality has increased by 27% in
5 years, accounting for more deaths than cervical cancer
since 2006, and is the second cause of death for women
aged 30–54. Incidence data is under-reported; 6,000 new
cases were detected in 1990, and a projected increase to
over 16,500 per year by 2020. Most cases are self-detected
and only 10% of all cases are detected in Stage I. All
Mexican women have access to free treatment either with
the social insurance (IMSS, ISSSTE), or through the Pop-
ular Health Insurance
6. Despite these entitlements, services
are lacking and early detection, particularly mammogra-
phy, is very limited. As of 2006, only 22% of women aged
40-69 reported having a mammogram. Barriers exist on
both the demand and the supply side [23].
The 2005 expenditure on breast-cancer detection pro-
grammes was 2.5% of total health expenditure during a 5-
year period (2000–2005); the percentage of women 40 to
69 years undergoing a screening procedure (mostly mam-
mography) increased from 12.6 to 21.6%. In 2003, there
were 100,000 mammograms performed in Mexico; in
2007, the number increased to 228,000. Public clinics and
hospitals around the country use more than 500 units of
mammography equipment. The government is interested in
having a cancer centre in most of the 32 states by 2012
[15].
Although prostate cancer incidence is increasing in the
country, there is no a national screening programme. Only
0.9% of total health expenditure was invested in prostate
cancer [24].
Country infrastructure for cancer treatment
Health-care supply is low in Mexico by OECD standards.
In virtually all dimensions for which health data are
available, Mexico lies well below the average. In 2006 the
doctor-to-population ratio was 1.9; scanners CT 3.6 per
million population, and radiation therapy equipment 1.3
per million population (Fig. 1)[ 5].
The system is profoundly unequal in terms of its
ﬁnancing and health outcome. Differences in resource
availability and quality also exist across institutions. Large
disparities in the health care facilities are present in Mexico
City, the northern and the southern states.
Most of the states have social security and private hos-
pitals, [25] however, cancer care for the uninsured is
irregular. Poverty and geographical barriers (i.e. remote
areas) create difﬁculties in obtaining cancer care, mostly
among the Mexican Indian natives, and in the southern
states. Financial restraints result in inequity in treatment
access as cancer patients may not be diagnosed, and may
be improperly staged or treated. In an effort to decrease the
care gap, a national cancer network has been implemented
by the MoH and State governments with 26 centres
improving access to evidence-based cancer treatments
nationally.
Mexico’s fragmented health system also inﬂuences
cancer care expenditure. Out-of-pocket payments are
standard for the poorest uninsured population seen by the
MoH. Although medical care, including surgical and
radiation therapy, is subsidised, pharmaceutical costs are
high. Financial restrictions make new chemotherapeutic
agents unavailable for the uninsured and occasionally for
social security (IMSS, ISSSTE) patients.
Although no accurate data are available, public cancer
treatment may be delayed for as long as 6 months due to
bureaucracy and work overload in the IMSS and ISSSTE,
while lack of knowledge in primary health care may delay
treatment for the uninsured. The waiting time for treatment
at the INCan is 2 months, mostly because overloaded
diagnostic procedures (chest X-ray, CT scans, PET scans)
delay proper staging. Waiting time for surgery is 5 weeks,
radiation therapy as long as 2 months, and chemotherapy
2 weeks.
7 Privately diagnosis, staging and treatment pro-
cedures can be carried out within a week. It is important to
mention that advanced disease is frequent at time of
Fig. 1 Radiation therapy equipment/million population
6 The Popular Insurance Scheme provides health coverage through
voluntary public insurance for persons not covered by social security
(IMSS, ISSSTE). It currently provides coverage for 266 medical
operations listed in the Universal Health Service Catalogue. A trust
was created to fund treatments which can cause catastrophic
expenditures, including childhood cancers, breast and cervical cancer.
7 However, often these patients are treated by general physicians for
several months before their referral to the Institute.
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123diagnosis in the public (MoH) and social security (IMSS,
ISSSTE) settings.
No uniform care is available, thus patients may receive
frontline or very poor treatment. This variation is further
contributed by the absence of national treatment guide-
lines, the fragmented health system and economic factors.
All cancer centres and tertiary care hospitals have skil-
led surgeons and standard radiation therapy procedures,
however, access to chemotherapy and mainly novel agents
may be limited. Recent IMSS budget constraints have
made access to new drugs difﬁcult. In contrast, ISSSTE
patients have access to novel drugs. Private patients have
private insurance or have personal wealth, enabling them to
pay out-of-pocket. In the public (MoH) setting, payments
are out-of-pocket unless a clinical trial is available.
Although most novel cancer treatments are licensed in
Mexico, only wealthy or insured private patients, those
receiving treatment at the ISSSTE, or patients enrolled in
clinical trials may have access to the new targeted
therapies.
Cancer care facilities
There are several large cancer centres in Mexico City:
INCan, Centro Hopitalario 20 de Noviembre, Instituto
Nacional de Pediatrı ´a, Hospital Infantil de Me ´xico, Hos-
pital de Pediatrı ´a IMSS, Hospital de Oncologı ´a IMSS,
Hospital General de Me ´xico SSA, Hospital Juarez SSA.
There are also a number of private hospitals equipped with
modern radiotherapy and medical oncology facilities.
Although insufﬁcient linear accelerators are available,
there are a large number of old cobalt units in many cancer
centres [15].
The Instituto Nacional de Cancerologia
The State Health services range from primary health-care
facilities to highly specialized National Institutes of Health
(INSalud). A high percentage of the population (57.9%)
[25], receive different types of medical attention at state
facilities.
The INSalud is a government organisation consisting of
12 institutions with different areas of specialisation. Its
purposes, in addition to medical treatment, are research and
medical education. The INCan is the largest cancer centre
nationally located centrally, operates under the INSalud
umbrella, and provides specialised cancer care to the
uninsured population. At INCan, an average of 4,000 new
patients are seen annually, mostly those living in Mexico
City and nearby states. The hospital is fully equipped for
diagnosis and provides oncologic treatment with radiation
therapy, surgery and chemotherapy. The medical staff
consist of highly trained oncologists (radiology, surgical
oncology, medical oncology, gynaecology, endoscopy,
immunology, infectious diseases, etc.). In addition, a can-
cer centre network consisting of 26 hospitals distributed
nationally provides cancer care to uninsured patients living
in the rest of the country with the majority of physicians
receiving training at INCan.
Colorectal cancer
According to 1998–2002 cancer registry data [26], CRC
represents 3.8% of new cancer cases, a 36% increase
during this period [27]. Furthermore, CRC mortality has
also increased over the same period.
The CRC incidence is higher in the northern states,
which, despite higher income, have poorer diet (low ﬁbre,
higher meat consumption and harmful fats) and lifestyle
placing them at risk for CRC development. In contrast, the
southern state population has lower income, impacting
meat and ﬁbre consumption [28]. Furthermore, incidence
varies among hospitals and their subsequent populations
(Table 1)[ 29].
Currently, more than 80% of patients are treated in
tertiary cancer centres with advanced tumours (Stages III
and IV) [30]. Although the reported mortality in Mexico is
less than 5/100,000 inhabitants, the lowest worldwide [31],
there is clear disagreement between tumour stage at diag-
nosis, scarcity of resources and reported mortality partic-
ularly due to the poor state of cancer data collection.
Late diagnosis of the CRC patients may be attributed to
referral bias and the absence of screening programmes, and
may contribute to the low survival of these patients [32].
There is no national CRC screening programme, how-
ever, local initiatives are implemented in some states or by
particular health providers. Although a national pro-
gramme is needed, it is important to acknowledge that
socio-cultural and economic factors associated with CRC
screening could affect its success [33]: lack of information
about CRC, machismo, embarrassment, diagnosis and test
costs, and low participation in CRC screening have all
been reported by Mexican communities living in the US
[31, 33–35].
CRC at the INCan
CRC patients seen at INCan increased more than 60% in a
ﬁve-year period. In a recent publication, Rizo-Rios et al.,
reported 789 new cases of CRC seen at the INCan in a
5 year period (2000–2004) [36]. The male/female ratio was
similar, and an age related increasing evidence was noted
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CRC treatment (non-pharmaceutical)
In Mexico, no treatment guidelines for CRC exist, how-
ever, surgical procedures are carried out according to
American guidelines found at the National Comprehensive
Cancer Network (NCCN).
Precise clinical staging often requires a diagnostic
colonoscopy and frequently a risk beneﬁt assessment is
used to decide surgical treatment (nutritional aspects, car-
diovascular risk, presence of distant metastasis, colonos-
copy results and possible beneﬁts of surgical resection).
Wide surgical resection of the involved bowel segment and
regional lymphatic drainage are standard surgical proce-
dures [37].
Operative treatment of rectal cancer includes en bloc
resection of the rectum as an intact unit with its lympho-
vascular drainage contained within the fascia propria of the
mesorectum using sharp dissection techniques (Total
Mesorectal Excision). Preservation of the anal sphincters
and avoidance of a permanent colostomy is preferred in
rectal cancer if eradication of the cancer with adequate
margins is also achieved. A temporarily diverting colos-
tomy may be necessary depending on intra-operative
ﬁndings. Transanal local excision of rectal cancer may be
appropriate and curative for selected patients with small,
early-stage and accessible tumours that exhibit favourable
histological features. Palliative treatment for unresectable
rectal cancers includes fulguration, laser photocoagulation,
radiation therapy and endostenting [37].
Due to surgical complexity, most CRC surgeries are
performed in large hospital facilities by trained surgeons
(gastroenterologist, oncologist and occasionally general
surgeons). At INCan, surgical procedures are performed
according to the NCCN Clinical Practice Guidelines in
Oncology.
Radiation therapy and chemotherapy are used for
advanced disease in conjunction with surgical resection
(according with NCCN Clinical Practice Guidelines in
Oncology). While radiation therapy has little role in man-
agement of colon cancer, it is an important treatment
modality for rectal cancer. Bulky rectal cancers may be
treated pre-operatively to improve resectability. For Stage-
II (invasion through the muscularis propria of the rectal
wall) or Stage-III rectal cancer (metastases to regional
lymph nodes), radiation therapy is a useful pre-operative or
postoperative adjunct and is also used in combination with
chemotherapy.
Pharmaceutical CRC treatment
Chemotherapy is essential to provide a chance of cure for
patients with more advanced disease, with 5-ﬂuorouracil
plus leucovorin (5-FU/LV) forming the basis of standard
treatment. Recently, new agents have become available
with a subsequent increase in life expectancy for patients
with Stage-IV disease from 5 to [20 months.
8 Treatment
facilities, use and adherence to clinical management
guidelines and access to new, effective agents may be
dramatically different within the country. Treatment costs
are particularly expensive for Stage III/IV.
In the public setting there is no uniform formula for
CRC treatment. Government employees (ISSSTE) are able
to access all types of CRC treatment, however, none of
these new agents are available for the IMSS CRC patients.
Out-of-pocket payments for pharmaceuticals at the Secre-
tariat of Health hospitals, including INCan, limit the pos-
sibility to access to novel drugs. These treatments may only
be available if patients are enrolled in pharmaceutical
industry-ﬁnanced clinical trials as there is no reimburse-
ment for the public sector. Private insurance may pay for
these new drugs, however, only a small percentage of the
population has access to private insurance.
Post-treatment surveillance
There are no national guidelines for post-curative treatment
surveillance. Postoperative surveillance varies according to
health provider type with private practice physicians often
Table 1 Incidence of CRC in four hospitals in Mexico City. (Modiﬁed from [29])
Hospital Population attended 1978 [%] 2003 [%] p
Hospital general Poor uninsured 15 36 \0.001
Hospital 20 de Noviembre Middle class government employees 20 51 \0.01
Instituto Nacional de CMNSZ Middle class uninsured 26 39 \0.106
Hospital Espan ˜ol Upper middle class, European 37 39 ns
8 Oral versions of traditional 5-ﬂuorouracil therapy (Capecitabine,
UFT), additional cytotoxic chemotherapy (Irinotecan, Oxaliplatin),
and new targeted biological treatments (Cetuximab, Bevacizumab).
S112 E. Verastegui, A. Mohar
123having closer follow-up, yet no speciﬁc protocol is fol-
lowed. For patients in the social security (IMSS, ISSSTE)
system, different follow-up protocols may be implemented
according to workload. At INCan, patients with resected
stage II or III CRC have:
• Clinical evaluations every 3 to 6 months for the ﬁrst
3 years, every 6 months during years 4 and 5, and
yearly thereafter
• Serum carcinoembryonic antigen levels every 3 months
for at least the ﬁrst 3 years after primary resection
• Colonoscopy once a year, if normal, 3 years later, and
if normal, at subsequent 5-year intervals
• Proctosigmoidoscopy: every 6 months for 5 years in
patients with low anterior resection
• Yearly CT scans of the chest and abdomen for 3 years
Conclusion
Colorectal cancer is one of the most common forms of
cancer, affecting large subsets of the population in devel-
oped nations and, increasingly, in low-middle-income
countries. Due to a combination of changes in population
age structure and vast transformations in lifestyle behav-
iour, an increasing proportion of individuals are at
increased risk of developing what is considered mostly to
be an avoidable disease.
Despite evidence on the effectiveness of some screening
procedures,theiruseremains lowinMexico.Social-cultural
factors may play a role in the under-utilisation of cancer
screening in addition to low levels of education, income and
limited government interest. Consequently, patients often
seek medical care at advanced stages of the disease.
If preventive programmes remain unchanged, the
increasing demands for curative health care may cause
great ﬁnancial and management challenges to the health
care system in Mexico.
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